These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 36060970)

  • 1. SGLT2 inhibitor treatment is not associated with an increased risk of osteoporotic fractures when compared to GLP-1 receptor agonists: A nationwide cohort study.
    Al-Mashhadi ZK; Viggers R; Starup-Linde J; Vestergaard P; Gregersen S
    Front Endocrinol (Lausanne); 2022; 13():861422. PubMed ID: 36060970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The risk of major osteoporotic fractures with GLP-1 receptor agonists when compared to DPP-4 inhibitors: A Danish nationwide cohort study.
    Al-Mashhadi ZK; Viggers R; Fuglsang-Nielsen R; Vestergaard P; Gregersen S; Starup-Linde J
    Front Endocrinol (Lausanne); 2022; 13():882998. PubMed ID: 36299454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: A population-based cohort study.
    Dong YH; Chang CH; Lin JW; Yang WS; Wu LC; Toh S
    Diabetes Obes Metab; 2022 Aug; 24(8):1623-1637. PubMed ID: 35491533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discrepancies in type of first major osteoporotic fracture and anti-osteoporotic therapy in elderly people with type 2 diabetes mellitus: A retrospective Danish cohort study.
    Viggers R; Starup-Linde J; Vestergaard P
    Bone; 2023 Jun; 171():116745. PubMed ID: 36965654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Sodium-Glucose Cotransporter 2 Inhibitors vs Glucagonlike Peptide-1 Receptor Agonists and Incidence of Dry Eye Disease in Patients With Type 2 Diabetes in Taiwan.
    Su YC; Hung JH; Chang KC; Sun CC; Huang YH; Lee CN; Hung MJ; Lai CC; Shao SC; Lai EC
    JAMA Netw Open; 2022 Sep; 5(9):e2232584. PubMed ID: 36136333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The associations of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as add-on to metformin with fracture risk in patients with type 2 diabetes mellitus.
    van Hulten V; Driessen JHM; Starup-Linde JK; Al-Mashhadi ZK; Viggers R; Klungel OH; Souverein PC; Vestergaard P; Stehouwer CDA; van den Bergh JP
    Diabetes Obes Metab; 2023 Nov; 25(11):3235-3247. PubMed ID: 37503747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of frailty on effectiveness and safety of GLP-1 receptor agonists versus SGLT2 inhibitors in people with type 2 diabetes in Taiwan: a retrospective, nationwide, longitudinal study.
    Hsiao FY; Tan EC; Meng LC; Lin YC; Chen HM; Guan ST; Tarng DC; Wang CY; Chen LK
    Lancet Healthy Longev; 2024 Sep; 5(9):100621. PubMed ID: 39284334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initiation of SGLT2 inhibitors and GLP-1 receptor agonists according to level of frailty in people with type 2 diabetes and cardiovascular disease in Denmark: a cross-sectional, nationwide study.
    Malik ME; Butt JH; Strange JE; Falkentoft AC; Jensen J; Andersson C; Zahir D; Fosbøl E; Petrie MC; Sattar N; McMurray JJV; Køber L; Schou M
    Lancet Healthy Longev; 2023 Oct; 4(10):e552-e560. PubMed ID: 37734395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Out-of-Pocket Costs and Treatment Intensification With an SGLT2 Inhibitor or GLP-1 RA in Patients With Type 2 Diabetes and Cardiovascular Disease.
    Luo J; Feldman R; Callaway Kim K; Rothenberger S; Korytkowski M; Hernandez I; Gellad WF
    JAMA Netw Open; 2023 Jun; 6(6):e2317886. PubMed ID: 37307000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of thyroid cancer associated with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: A population-based cohort study.
    Bea S; Son H; Bae JH; Cho SW; Shin JY; Cho YM
    Diabetes Obes Metab; 2024 Jan; 26(1):108-117. PubMed ID: 37735822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Efficacy of Alendronate Versus Denosumab on Major Osteoporotic Fracture Risk in Elderly Patients With Diabetes Mellitus: A Danish Retrospective Cohort Study.
    Viggers R; Al-Mashhadi Z; Starup-Linde J; Vestergaard P
    Front Endocrinol (Lausanne); 2021; 12():826997. PubMed ID: 35154013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
    Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The comparative cardiovascular and renal effectiveness of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A Scandinavian cohort study.
    Ueda P; Wintzell V; Dahlqwist E; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Melbye M; Hviid A; Svanström H; Pasternak B
    Diabetes Obes Metab; 2022 Mar; 24(3):473-485. PubMed ID: 34738703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lower risk of death and cardiovascular events in patients with diabetes initiating glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors: A real-world study in two Italian cohorts.
    Baviera M; Genovese S; Lepore V; Colacioppo P; Robusto F; Tettamanti M; D'Ettorre A; Avanzini F; Fortino I; Nicolucci A; Roncaglioni MC; Giorgino F
    Diabetes Obes Metab; 2021 Jul; 23(7):1484-1495. PubMed ID: 33606897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections: A Propensity Score-matched Population-based Cohort Study.
    Alkabbani W; Zongo A; Minhas-Sandhu JK; Eurich DT; Shah BR; Alsabbagh MW; Gamble JM
    Can J Diabetes; 2022 Jun; 46(4):392-403.e13. PubMed ID: 35513988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of SGLT2 Inhibitors vs GLP-1 RAs and Anemia in Patients With Diabetes and CKD.
    Hu JC; Shao SC; Tsai DH; Chuang AT; Liu KH; Lai EC
    JAMA Netw Open; 2024 Mar; 7(3):e240946. PubMed ID: 38436955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Sodium-Glucose Cotransporter-2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes.
    Zhuo M; Hawley CE; Paik JM; Bessette LG; Wexler DJ; Kim DH; Tong AY; Kim SC; Patorno E
    JAMA Netw Open; 2021 Oct; 4(10):e2130762. PubMed ID: 34705014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between sodium glucose co-transporter 2 inhibitors and incident glaucoma in patients with type 2 diabetes: A multi-institutional cohort study in Taiwan.
    Shao SC; Su YC; Lai EC; Chang KC; Lee CN; Hung MJ; Lai CC; Huang FC; Hung JH
    Diabetes Metab; 2022 Jan; 48(1):101318. PubMed ID: 35017100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists according to the 2019 ESC guidelines and the 2019 ADA/EASD consensus report in a national population of patients with type 2 diabetes.
    Lim CE; Pasternak B; Eliasson B; Danaei G; Ueda P
    Eur J Prev Cardiol; 2023 Jun; 30(8):634-643. PubMed ID: 36582120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effectiveness and safety of sodium-glucose cotransporter-2 inhibitors versus metformin in patients with type 2 diabetes: An observational study using data from routine care.
    Fralick M; Schneeweiss S; Redelmeier DA; Razak F; Gomes T; Patorno E
    Diabetes Obes Metab; 2021 Oct; 23(10):2320-2328. PubMed ID: 34169619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.